Post Archive by Year

Montréal, December 18, 2019 – CQDM congratulates Theratechnologies for reporting positive results on TH-1902, a docetaxel conjugate for the treatment of triple-negative breast cancer (TNBC), during the prestigious San Antonio Breast Cancer Symposium held on December 10-14 in San Antonio (Texas, USA). Theratechnologies also announced that the Food and Drug Administration (FDA) has approved the launch of the Phase 1 clinical … Read More

Private companies based in Quebec with biopharmaceutical-related activities are invited to propose postdoctoral internship positions for new doctoral graduates, future awardees of the Gordon Shore Prize. Award sponsors, CQDM, Diazon Pharmaceuticals and Mitacs will finance 50% of these postdoctoral internships. The company must agree to pay the other half of the new graduate’s salary. The application and the obtaining of the … Read More

Montreal, November 29, 2019 – The Chairman of the Scientific Advisory Board, Daniel Hétu, and the President and CEO of CQDM, Diane Gosselin, are pleased to announce the appointment of two new members to CQDM’s governance. Bernard Massie, former Director General, Human Health Therapeutics at the NRC, and Cameron Black, Executive Vice President, Discovery at Repare Therapeutics will be joining CQDM’s Scientific … Read More

The project led by Michel Bouvier and Domain Therapeutics with the support of CQDM is awarded the RSRI Recognition Award at the ADRIQ Innovation Prize Gala Montreal, November 22, 2019 – CQDM is proud to announce that the project led by Michel Bouvier from the Institute for Research in Immunology and Cancer (IRIC) of the Université de Montréal and the biotech Domain … Read More

Zealand Pharma’s acquisition of Encycle Therapeutics highlights the impact of CQDM’s early support on Canadian biotech company creation and success. Montreal, November 11th, 2019 – CQDM commends Encycle Therapeutics for their acquisition by Zealand Pharma (NASDAQ: ZEAL)[1]. CQDM is proud to have supported Encycle Therapeutics and its technology platform from the very beginning in partnership with Toronto Innovation Acceleration Partnership … Read More

CQDM, the Canadian Cancer Society and Theratechnologies grant $1.7M to UQAM for the development of a new therapy targeting the most aggressive form of breast cancer Montreal, October 4, 2019. – CQDM, in partnership with the Canadian Cancer Society (CCS) and Theratechnologies, is proud to announce that it will be granting $1.7M to Université du Québec à Montréal (UQAM) to … Read More

New appointments to CQDM’s Board of Directors and Scientific Advisory Board Montreal, September 23, 2019 – The chairman of the Board of Directors, Richard Fajzel, and Diane Gosselin, President and CEO of CQDM, are very pleased to announce the appointment of four new members overseeing CQDM’s governance. Daniel Hétu, Managing Director of Lumira Ventures, Sarah Jenna, co-founder and CEO of My … Read More

PARTENAR-IA, a funding initiative to support public-private AI-based research projects ! DEADLINE: OCTOBER 15th, 2019 Montreal, August 20th, 2019 – The PARTENAR-IA initiative aims to accelerate the design and development of Artificial Intelligence (AI) technologies applicable in the biopharmaceutical sector by participating in the funding of collaborative research projects carried out in a Quebec public research institution. The grant can reach … Read More

The SynergiQc-International program is geared to support public/private research with partners outside the province of Quebec ! DEADLINE: OCTOBER 7th, 2019 Montreal, July 16th, 2019 – CQDM has launched the SynergiQc-International funding program that may cover up to 50% of R&D expenses incurred in Quebec as part of a public/private partnership in the biopharmaceutical field, up to a maximum of $500,000. … Read More

Amgen and Takeda join the Quantum Leap project led by CQDM and Feldan Therapeutics, to improve a novel intracellular delivery technology Philadelphia, June 4th, 2019 – CQDM is pleased to announce that following their recent enrollment in the consortium, Amgen and Takeda will be joining the syndicate of pharma companies to fund the Quantum Leap project recently launched by Feldan … Read More